Abstract: Disclosed herein is a Dynamic Random Access Memory-Based Content-Addressable Memory (DRAM-CAM) architecture and methods relating thereto. The DRAM-CAM architecture can include a memory array, with the data organized into blocks including rows and columns. Input data can be converted into a format with first and second groups of columns. Each first group can correspond to one or more rows of the input data, and each second group can include one or more null columns. A query can be received and loaded into an available column of the second group, and pattern matching can be performed on the data to identify occurrences of elements defined by the query. The pattern matching can be performed concurrently on the first groups of columns and the available columns bit by bit. Results can include a count or location of each identified element.

Abstract: Provided are biomarkers for parenteral nutrition associated cholestasis (PNAC) in subjects, especially infants receiving parenteral nutrition (PN). Using such biomarkers provide methods of diagnosing and/or assessing risk of PNAC in a subject, including screening a sample from a subject believed to be at risk for PNAC for one or more biomarkers of PNAC. The biomarkers can include one or more fecal metabolites. Such biomarkers and associated methods provide neonatal intensive care unit clinicians with an additional tool for early identification of PNAC risk. Early identification of high-risk infants would enable clinicians to confidently optimize caloric nutrition with PN for infants at low risk of developing PNAC and enable proactive mitigation with alterations to the administered PN.

Abstract: Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

Abstract: An integrated bioreactor and reseeding chamber system and a separate bioreactor and complimentary reseeding chamber system comprising a bioreactor and a separate reseeding chamber. The bioreactor comprises a bioreactor chamber; a first groove attached to the bioreactor chamber; a second groove removably attached to the bioreactor chamber. A first bar and a second bar may be removably inserted into the first groove and the second groove respectively. Each of the first bar and the second bar may have at least an oval hole. At least a crossbar is attached substantially perpendicularly to the first bar and the second bar to form a crossbar-bars construct through the oval holes. A knob may be installed on each of the crossbars. The reseeding chamber may comprise dividers fixedly attached to a bottom of the reseeding chamber.

Abstract: For trapping atoms, an x-axis wire carries an x-axis current I0cos ?t, wherein I0 is current amplitude, ? is a trap field frequency, and t is time. A y-axis wire carries a y-axis current I0sin ?t, the y-axis wire intersecting the x-axis wire at a cross center. A ?-field coil generates a transverse magnetic bias field ? rotating about the cross center and perpendicular to a z axis. A ?-field coil generates a longitudinal magnetic bias field ? rotating about the cross center and perpendicular to the z axis. The x-axis wire, the y-axis wire, the transverse magnetic bias field ?, and the longitudinal magnetic bias field ? form a time-averaged trap along the z axis near the cross center.

Abstract: An electrochemical device for identifying electroactive analytes. The device includes a substrate; a sample region; a counter electrode; a reference electrode; a working electrode disposed in communication with the substrate, and the working electrode may be an electron conducting fiber. Further, the counter electrode, reference electrode, and working electrode are partially disposed in the sample region configured to be exposed to the electroactive analyte. Further yet, a counter electrode channel, reference electrode channel, and working electrode channel are disposed in the substrate configured to: accommodate each of the counter electrode, reference electrode, and working electrode, respectively, for placement in the respective channels.

Abstract: The capillary transfer technology presented here represents a powerful approach to transfer soft films from surface of liquid onto a solid substrate in a fast and defect-free manner. The fundamental theoretical model and transfer criteria validated with comprehensive experiments and finite element analyses, for the first time provides a quantitative guide and optimization for the choice of material systems, operating conditions and environments for scalable on-demand transfers with high yield. The intrinsically moderate capillary transfer force and externally selectable transfer direction offer robust capabilities for achieving deterministic assembly and surface properties of structures with complex layouts and patterns for potentially broad applications in the fabrication of flexible/stretchable electronics, surface wetting structures and optical devices.

Abstract: A protective vest device that will adequately secure an infant from the ability to self-dislodge medical life-sustaining supply lines or equipment, while also supporting proper body alignment. The protective device mitigates self-dislodgement while allowing for free movement and proper alignment of infant's arms and hands and which are allowed to touch one another, thereby not inhibiting the ability to explore and expand brain development through tactile stimulation and therefore fostering healthy neuronal pathways of the infant. The fostering healthy neuronal pathways is provided by, for example, allowing the hands to touch one another as the infant develops a sense of where it is in space and time as it continues to grow outside of the womb.

Abstract: Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G?(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G?(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.

Abstract: Provided are methods for treating subjects with coronavirus infections. The methods include providing a subject infected with a coronavirus resulting in a prothrombotic condition in addition to being infected by a coronavirus, and administering to the subject an angiotensin (1-7) peptide or an analog or derivative thereof, a Mas Receptor (MasR) agonist, or any combination thereof. The subject may be suffering from COVID-19 disease, including but not limited to a thrombotic complication, an adverse pregnancy outcome, and/or a complication resulting from an underlying prothrombotic state. Also provided are compositions that include Ang (1-7) peptides, analogs, and/or derivatives thereof that are associated with degradable and/or non-degradable polymers having electrostatic interactions therewith, hydrophobic interaction therewith, hydrogen bonding interactions therewith, or any combination thereof.

Abstract: The present application discloses a novel fusion peptide of IL-2 and IL-33 and its use. It comprises a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment or homolog thereof, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment or homolog thereof. The two portions can be linked by a linker sequence. The application discloses that combination therapies using IL-2 and IL-33 or a therapy using the IL233 fusion protein are effective in preventing or treating diseases and disorders such as autoimmune diseases and disorders, inflammation, etc. Depending on the subject's disease or disorder, the compositions of the invention are useful for preventing certain symptoms, treating the disease, and alleviating at least some of the symptoms.

Abstract: Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides prodrugs of compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both, according to formula (I) as described herein. Formula I compounds are useful in the treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. The invention also provides pharmaceutical compositions of Formula I compounds.

Abstract: Compositions and methods for regenerating pancreatic islet viability and/or cell proliferation in vitro, ex vivo, and/or in vivo; and/or for regenerating glucose-stimulated insulin secretion; and/or for regenerating viability and/or cell proliferation of a transplanted pancreatic islets; and/or for preventing and/or inhibiting rejection of a transplanted islets; and/or for pancreatic islet transplantation; and/or for treating a symptom of a condition, disorder, or disease associated with abnormal insulin responsiveness to glucose are provided. In some embodiments, the compositions include a peptide and/or a pharmaceutically acceptable salt thereof, and/or a biologically active fragment, analog, or derivative thereof, wherein the peptide, the pharmaceutically acceptable salt thereof, and/or the biologically active fragment, analog, or derivative thereof has an amino acid sequence of any of SEQ ID NOs: 1-60, or any combination thereof.

Abstract: Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

Abstract: Provided are methods for enhancing immunosuppression in the lung of a subject, In some embodiments, the methods include administering to the subject a composition comprising at least one eosinophil recruiting agent, wherein the administering is in an amount and via a route of administration sufficient to induce recruitment of eosinophils to the lung of the subject to thereby enhance immunosuppression in the lung of the subject. Also provided are methods for enhancing tolerance to lung transplants, enhancing recruitment of eosinophils to the lungs, modulating T cell-mediated immune responses in the lungs, and reducing TCR signal transduction in the lungs.

Abstract: The disclosure provides compounds that inhibit protein tyrosine phosphatase, such as protein tyrosine phosphatase 4 A3 (PTP4A3). The disclosure also provides pharmaceutical compositions, uses, and methods of using the compounds, such as in the treatment of cancers.

Abstract: Methods are disclosed for generating, manipulating, and controlling non-Gaussian quantum states in continuous variable cluster quantum states usable for quantum computing. Some methods can be used to generate, transport, and enlarge Schrödinger-Cat states embedded in the CV cluster quantum state. Some methods can be used to transform Schrödinger-Cat states embedded in the CV quantum cluster state to grid states (such as Gottesman-Kitaev-Preskill states) and enlarge the grid states. In certain embodiments, some of the methods may be used to generate and control non-Gaussian states in macronode cluster quantum states such as cluster states comprising two-mode macronodes.

Abstract: Non-degradable, non-immunogenic microporous hydrogel compositions are provided. Such hydrogel compositions consist of flowable hydrogel particles comprising a bioinert polymeric backbone, including for example a poly(ethylene glycol)(PEG)-based polymeric backbone, an annealing component comprising a physiologically-stable, radically polymerizable alkene, including for example methacrylamide, and a heparin compound. Methods of treating glottic incompetence and/or providing laryngeal reconstruction are also provided. Such methods consist of providing a subject suffering from glottic incompetence and/or in need of laryngeal reconstruction, and administering a non-degradable, non-immunogenic microporous hydrogel composition disclosed herein.

Abstract: The gene responsible for encoding SERT has a functional polymorphism at the 5?-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3? UTR SNP rs1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on variations in the polymorphisms of the SERT gene as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders.

Abstract: An apparatus related method for measuring a property of a target material. The system may include a pump device that generates a pump beam. A modulation device may receive the pump beam and generate a modulated pump beam by modulating an intensity amplitude of the pump beam, which may be directed to the target material. A probe device may generate a probe beam, which is directed to the target material. A part of the probe beam may be reflected off of the target material, and has similar frequency characteristic as the modulated pump beam. A detection device may detect the reflected probe beam and produce a signal. An analyzing device may receive the signal and calculate the target material property by comparing the modulated frequency characteristics of the signal to those of the pump beam. At least one of the pump and the probe beams may be infrared light.